Mark Lamotte
-
- Diabetes Treatment and Management 33
- Diabetes Management and Research 21
- Nephrology top 5%
-
- Antiplatelet Therapy and Cardiovascular Diseases 7
- Economics and Econometrics top 5%
- Health Systems, Economic Evaluations, Quality of Life 32
- Pharmaceutical Economics and Policy 13
-
- Metabolism, Diabetes, and Cancer 9
-
- Lipoproteins and Cardiovascular Health 8
-
- Pharmacology and Obesity Treatment 6
Mark Lamotte
120 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 126
- Endocrinology, Diabetes and Metabolism 564
- Nephrology 107
- Cardiology and Cardiovascular Medicine 306
- Economics and Econometrics 265
- Pediatrics, Perinatology and Child Health 170
Countries citing papers authored by Mark Lamotte
This map shows the geographic impact of Mark Lamotte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lamotte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lamotte more than expected).
Fields of papers citing papers by Mark Lamotte
This network shows the impact of papers produced by Mark Lamotte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lamotte. The network helps show where Mark Lamotte may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark Lamotte, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 10 | |
| 2 | 2024 | 1 | |
| 3 | 2023 | 2 | |
| 4 | 2021 | 1 | |
| 5 | 2021 | 15 | |
| 6 | 2018 | 1 | |
| 7 | 2016 | 2 | |
| 8 | 2016 | 1 | |
| 9 | 2015 | 1 | |
| 10 | 2015 | 1 | |
| 11 | 2014 | 1 | |
| 12 | 2013 | 0 | |
| 13 | 2013 | 0 | |
| 14 | 2013 | 1 | |
| 15 | 2012 | 10 | |
| 16 | 2011 | 2 | |
| 17 | Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes. | 2009 | 8 |
| 18 | [The cost of complicated acute urinary retention: a patient chart analysis in Belgium]. | 2005 | 3 |
| 19 | [Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective]. | 2004 | 11 |
| 20 | Coste-efectividad de irbesartan en pacientes hipertensos con nefropatía diabética tipo II: una perspectiva española | 2004 | 3 |
About Mark Lamotte
Mark Lamotte is a scholar working on Endocrinology, Diabetes and Metabolism, Family Practice and Economics and Econometrics, having authored 127 papers that have together received 1.6k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (33 papers), Health Systems, Economic Evaluations, Quality of Life (32 papers), Diabetes Management and Research (21 papers), Pharmaceutical Economics and Policy (13 papers), Metabolism, Diabetes, and Cancer (9 papers), Lipoproteins and Cardiovascular Health (8 papers), Antiplatelet Therapy and Cardiovascular Diseases (7 papers) and Pharmacology and Obesity Treatment (6 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (564 citations), Nephrology (107 citations) and Cardiology and Cardiovascular Medicine (306 citations). Mark Lamotte has collaborated with scholars based in United Kingdom, Belgium and United States. Frequent co-authors include Lieven Annemans, V. Foos, Phil McEwan, James L. Palmer, David Grant, Adam Lloyd, Laetitia Gerlier, R. Pieters, Han Myint and K Moeremans. Their work appears in journals such as Value in Health, Journal of Medical Economics, Diabetes Therapy, PharmacoEconomics and Cost Effectiveness and Resource Allocation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.